Analysis of the main mechanism of action and therapeutic efficacy of pemetinib

Pemigatinib, also known as pemetinib, is an oral small molecule targeted anti-cancer drug. It is mainly used to treat malignant tumors caused by FGFR (fibroblast growth factor receptor) gene changes. It has shown significant efficacy in the treatment of cholangiocarcinoma (especially locally advanced or metastatic tumors). In 2020, pemetinib was approved by the U.S. FDA for the treatment of patients with advanced cholangiocarcinoma carrying FGFR2 fusions or rearrangements, becoming the first approved therapy for this target.

1. Mechanism of action: selective inhibitionFGFRpathway

The main pharmacological effect of pemetinib is to selectively inhibit the tyrosine kinase activities of FGFR1, FGFR2 and FGFR3. FGFR family members play key roles in normal cell growth, differentiation, migration, and angiogenesis. However, in some cancers, these receptors are activated due to genetic mutations, fusions, or amplifications, thereby promoting abnormal tumor cell growth, resistance to apoptosis, and metastasis.

FGFR2fusion or rearrangement is a common genetic abnormality in patients with cholangiocarcinoma. About 10%–16% of cholangiocarcinoma patients have such mutations. By targeting this mutation target, pemetinib inhibits the abnormal activation of the FGFR signaling pathway, thereby inhibiting the growth of cancer cells, promoting apoptosis and preventing tumor spread. This type of targeted treatment is more targeted than traditional chemotherapy, and the side effects are relatively more controllable.

2. Clinical indications and application prospects

The current main approved indication for pemetinib is advanced or metastatic cholangiocarcinoma, especially in patients who have received at least one systemic therapy and carry FGFR2 gene fusions or rearrangements. According to FIGHT-202clinical study data, among this population, the objective response rate (ORR) of pemetinib reaches 35.5%, and some patients achieve complete remission or sustained disease control, which is significantly better than previous treatments.

In addition, studies are exploring its efficacy against other tumor types carrying FGFR alterations, including bladder cancer, endometrial cancer, lung cancer, and others. These are still in the clinical trial stage, but studies have shown that FGFR mutations occur in a certain proportion in a variety of tumors, so pemetinib is expected to expand into a wider range of targeted treatments.

3. Adverse reactions and medication precautions

Although pemetinib is highly targeted, a certain degree of adverse reactions may still occur during clinical use. Common side effects include hyperphosphatemia, stomatitis, rash, diarrhea, alopecia, nail abnormalities, fatigue, etc. Among them, hyperphosphatemia is the most common adverse event, which may be related to the role of the FGFR pathway in regulating phosphate metabolism and needs to be managed by adjusting diet or using phosphate binders.

In addition, some patients may experience ocular toxicity, such as dry eye syndrome, blurred vision, and even central serous chorioretinopathy (CSCR), so regular vision examinations and ophthalmological evaluations should be performed during medication. Patients with hepatic and renal insufficiency should also use it with caution under the guidance of a doctor, and adjust the dose or discontinue the drug if necessary.

During medication, attention should be paid to drug interactions, especially to avoid co-administration with CYP3A4 strong inhibitors or inducers to avoid affecting drug metabolism and blood concentration. At the same time, it is contraindicated for pregnant women and lactating women, and women of childbearing age should take reliable contraceptive measures during use.

4. Therapeutic value and market prospects

With the development of genetic testing technology and the promotion of precision medicine concepts, the FGFR pathway has gradually received attention as a new generation of tumor targets. As the first approved targeted drug targeting FGFR2 fusion, pemetinib not only fills the gap in the treatment of advanced cholangiocarcinoma, but also provides a template for the development of related targets.

In China, pemetinib has been approved for marketing as an imported drug. Although it has not yet been included in medical insurance, it can be purchased through special drug channels in some big city hospitals. In foreign markets, the original version of the drug was jointly developed by Incyte and BridgeBio Pharma. The price is higher, but there are also generic drugs on sale in Laos and India. The price is relatively affordable and suitable for patients with financial burdens.

In general, pemetinib, as an important drug targeting FGFR mutations, has clear efficacy in specific groups and is an important breakthrough in the current precision treatment of cholangiocarcinoma. In the future, with the expansion of indications and the gradual improvement of the price mechanism, its prospects in the domestic and foreign tumor treatment markets will be broader. At the same time, carrying out genetic testing to screen suitable drug users will also become a key step in clinical practice.

Reference materials:https://go.drugbank.com/drugs/DB15102